Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Stimatix GI's AOS-C1000 colostomy management device meets primary, secondary endpoints in pre-clinical studies

Stimatix GI reported that the AOS-C1000(TM), a unique colostomy management device, met primary and secondary endpoints in pre-clinical in-vivo animal studies. The study was conducted under the direction of Dr. Ron Greenberg, Senior Surgeon, Department of Surgery, Sourasky Medical Center, Tel Aviv Israel. Primary endpoints of repeatable stoma sealing for continence control as well as secondary endpoints regarding tissue pathology and survival were met confirming the AOS-C1000(TM) as capable of enabling repeatable colostomy site (stoma) sealing for continence control.

13 Dec 2010

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Pfizer Inc. announced that Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, affordable and accelerated basis to the least developed countries.

13 Dec 2010

Scientists create functioning human intestinal tissue from pluripotent stem cells

For the first time, scientists have created functioning human intestinal tissue in the laboratory from pluripotent stem cells.

13 Dec 2010

Chinese study examines association between alcohol intake, CAD

Among a large number of Chinese men presenting with chest pain or EKG changes, sequential subjects undergoing cardiac angiography were evaluated for obstructive coronary artery disease lesions according to their reported recent alcohol intake. The study population consisted of 1,476 consecutive men 36 to 84 years of age; participants were categorized as nondrinkers, light drinkers, moderate drinkers, or heavy drinkers.

10 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Patients treated by Welsh hospitals for upper gastrointestinal (GI) bleeding were 41% more likely to die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics.

9 Dec 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

The management of children with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis has evolved significantly over the past decade. With a surge of pediatric research in the field, quality of life has become an important focus of study, as indicated by the number of related abstracts that will be presented at the 2010 Advances in Inflammatory Bowel Diseases, the Crohn's & Colitis Foundation's Clinical & Research Conference beginning tomorrow in Hollywood, Florida.

9 Dec 2010

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved.

9 Dec 2010

ChipDX validates genetic signature for early-stage colon cancer

ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.

8 Dec 2010

Study shows testing between colonoscopies helps detect CRC, advanced tumors

Among patients with a family or past history of colorectal cancer, testing between colonoscopies helps detect CRC and advanced tumors that are either missed or develop rapidly, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

8 Dec 2010

First standard-of-care guidelines for children with congenital muscular dystrophy

In 2008, Eunice and Andrew Kim were facing a situation that would bewilder any parents: Two expert pediatric surgeons were giving opposing advice about treatment for their daughter.

8 Dec 2010

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.

8 Dec 2010

Early group daycare exposure protects kids from infections later: Study

A new study reassures parents that although young kids might get sick more often when they first start group childcare, these same kids get fewer infections later in their childhood. About one in three U.S. kids receives organized childcare before reaching kindergarten age, whether at a daycare center or a school.

7 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

An international team of researchers led by the University of East Anglia (UEA) have developed a new kind of endoscope to aid the early detection and diagnosis of inflammatory bowel disease.

7 Dec 2010

New tool for predicting disease course in children with Crohn's disease

A new study published in the journal Inflammatory Bowel Diseases develops a computer based visual tool that can be used in “real time” to show pediatric Crohn’s disease (CD) patients’ predicted disease course and how this might be influenced by different treatment options.

6 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that the U.S. Food and Drug Administration's (FDA) Gastroenterology and Urology Devices Panel recommended approval of Solesta™ as a treatment for fecal (bowel) incontinence, a condition afflicting many Americans, primarily women.

3 Dec 2010

Loyola nurses honored

Loyola University Health System revenue specialist Judy Williams, RN, CEN, TNS, recently took on a nontraditional nursing role, which resulted in a significant cost savings for the organization. Williams oversees fiscal responsibility for the Emergency Department. In this position, she has identified opportunities to overcome billing obstacles through intradepartmental collaboration and nurse education on proper documentation for reimbursement.

3 Dec 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Stimatix GI's AOS-C1000 colostomy management device meets primary, secondary endpoints in pre-clinical studies

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Scientists create functioning human intestinal tissue from pluripotent stem cells

Chinese study examines association between alcohol intake, CAD

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Health care systems inadequate for managing acute GI hemorrhage outside of normal hours

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

Teva, Active Biotech report positive initial results from laquinimod Phase III study in multiple sclerosis

ChipDX validates genetic signature for early-stage colon cancer

Study shows testing between colonoscopies helps detect CRC, advanced tumors

First standard-of-care guidelines for children with congenital muscular dystrophy

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Early group daycare exposure protects kids from infections later: Study

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

New endoscope aids in early detection and diagnosis of inflammatory bowel disease.

New tool for predicting disease course in children with Crohn's disease

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

Loyola nurses honored

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in